James Tearse, MD
Ophthalmology · Redwood City, CANPI 1811099435
Payments from drug & device makers
Across 375 payments — averaging $119.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$20K
- Sight Sciences, Inc.$7K
- Biotissue Holdings Inc.$4K
- Bausch & Lomb Americas Inc.$3K
- Katena Products, Inc. (dba Corza Medical)$2K
- Kala Pharmaceuticals, Inc.$2K
- plus $7K from 17 others
What the payments were for
- Royalty or licence$2,9997%
- Consulting fees$7,23516%
- Speaking & faculty fees$17,97640%
- Travel & lodging$4,79811%
- Food & beverage$11,81326%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 77 | $19,912 |
| Sight Sciences, Inc. | 22 | $7,009 |
| Biotissue Holdings Inc. | 43 | $3,892 |
| Bausch & Lomb Americas Inc. | 20 | $3,127 |
| Katena Products, Inc. (dba Corza Medical) | 3 | $1,875 |
| Kala Pharmaceuticals, Inc. | 17 | $1,619 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 11 | $1,349 |
| Dompe US, Inc. | 14 | $1,094 |
| Oyster Point Pharma, Inc. | 28 | $898 |
| Novartis | 49 | $801 |
| Tarsus Pharmaceuticals, Inc. | 17 | $729 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 22 | $605 |
| AbbVie(2 entities) | 14 | $490 |
| Alcon | 11 | $349 |
| Eyevance Pharmaceuticals LLC | 3 | $196 |
| Aerie Pharmaceuticals, Inc. | 4 | $178 |
| Harrow Eye, LLC | 3 | $166 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $141 |
| Omeros Corporation | 2 | $130 |
| Shire North American Group Inc | 8 | $124 |
| Mallinckrodt Hospital Products Inc. | 2 | $71 |
| ANI Pharmaceuticals, Inc. | 2 | $44 |
| Akorn, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,821 in reported general payments places this provider in the 90th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 70 | $113,269 |
| RestasisCyclosporine | 36 | $53,968 |
| XdemvyLotilaner | 25 | $46,668 |
| MieboPerfluorohexyloctane/Pf | 40 | $29,667 |
| RocklatanNetarsudil Mesylat/Latanoprost | 33 | $20,416 |
| Cyclosporine | 25 | $10,819 |
| LumiganBimatoprost | 12 | $8,361 |
| ProlensaBromfenac Sodium | 23 | $7,566 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $5,049 |
| Prednisolone Acetate | 44 | $1,954 |
| Doxycycline Monohydrate | 56 | $1,628 |
| Loteprednol Etabonate | 13 | $1,344 |
| Timolol Maleate | 27 | $1,153 |
| Ketorolac Tromethamine | 47 | $1,114 |
| Latanoprost | 101 | $1,068 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $3,127 | $142,936110 claims |
| AbbVieRestasis, Lumigan | $490 | $62,33048 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $729 | $46,66825 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $178 | $20,41633 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $605 | $8,90936 claims |
| AlconSimbrinza | $349 | $5,04915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Redwood City
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.